For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Collaboration revenue - related party | 0 | |||
| Research and development | 150,152,000 | |||
| General and administrative | 56,781,000 | |||
| Impairment of long-lived asset | 2,382,000 | |||
| Total operating expenses | 209,315,000 | |||
| Loss from operations | -209,315,000 | |||
| Interest and other income, net | 19,289,000 | |||
| Interest expense | 1,075,000 | |||
| Other income (expense), net | 215,000 | |||
| Total other income (expense), net | 18,429,000 | |||
| Loss before income taxes | -190,886,000 | |||
| Tax benefit at federal statutory rate | -40,086,000 | |||
| Research tax credits | 1,783,000 | |||
| Change in valuation allowance | 35,414,000 | |||
| Stock-based compensation | 6,280,000 | |||
| Other | 175,000 | |||
| Other adjustments | 0 | |||
| Income tax expense | 0 | |||
| Net loss | -190,886,000 | |||
| Net unrealized gain on available-for-sale investments | 358,000 | |||
| Net comprehensive loss | -190,528,000 | |||
| Basic EPS | -0.87 | |||
| Diluted EPS | -0.87 | |||
| Basic Average Shares | 220,622,669 | |||
| Diluted Average Shares | 220,622,669 | |||
Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. (ALLO)